Table 3.
Characteristic | Absolute LS, % | Absolute GCS, % | GRS, % | e’ velocity, cm/s | SRE, 1/s | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
β | SE | P-value | β | SE | P-value | β | SE | P-value | β | SE | P-value | β | SE | P-value | |
Age, per 10 y increase | −0.09 | 0.07 | 0.20 | 0.89 | 0.12 | <0.0001 | 0.71 | 0.28 | 0.01 | −0.56 | 0.03 | <0.0001 | −0.06 | 0.01 | <0.0001 |
Female sex | −1.18 | 0.18 | <0.0001 | −0.07 | 0.31 | 0.82 | −0.41 | 0.73 | 0.58 | 0.16 | 0.08 | 0.07 | −0.06 | 0.02 | <0.0001 |
Hypertension | −0.32 | 0.19 | 0.09 | 1.90 | 0.31 | <0.0001 | 1.36 | 0.75 | 0.07 | −1.01 | 0.08 | <0.0001 | −0.12 | 0.01 | <0.0001 |
SBP, per 10 mm Hg increase | −0.19 | 0.05 | <0.0001 | 0.32 | 0.08 | 0.00 | 0.38 | 0.19 | 0.05 | −0.19 | 0.02 | <0.0001 | −0.03 | 0.00 | <0.0001 |
DBP, per 10 mm Hg increase | −0.49 | 0.09 | <0.0001 | 0.07 | 0.16 | 0.64 | 0.14 | 0.37 | 0.70 | −0.13 | 0.04 | <0.0001 | −0.04 | 0.01 | <0.0001 |
Antihypertensive medication use | −0.01 | 0.19 | 0.97 | 1.96 | 0.31 | <0.0001 | 1.78 | 0.74 | 0.02 | −0.93 | 0.08 | 0.0001 | −0.10 | 0.02 | <0.0001 |
BMI, per 5 kg/m2 increase | −0.17 | 0.08 | 0.02 | 0.22 | 0.13 | 0.09 | 0.58 | 0.31 | 0.06 | −0.18 | 0.04 | <0.0001 | −0.02 | 0.01 | <0.0001 |
Smoking | 0.08 | 0.20 | 0.69 | −0.27 | 0.35 | 0.43 | −0.38 | 0.82 | 0.64 | 0.06 | 0.09 | 0.55 | 0.00 | 0.02 | 0.86 |
Fasting glucose, per 10 mg/dl increase | −0.08 | 0.03 | 0.00 | 0.05 | 0.04 | 0.24 | 0.01 | 0.10 | 0.93 | −0.05 | 0.01 | <0.0001 | −0.01 | 0.00 | <0.0001 |
LVMI, per 10 g/m2 increase | −0.11 | 0.05 | 0.02 | 0.24 | 0.08 | <0.0001 | 0.24 | 0.18 | 0.17 | −0.13 | 0.02 | <0.0001 | −0.02 | 0.00 | <0.0001 |
LVEF, per 5% decrease | −0.40 | 0.08 | <0.0001 | −0.77 | 0.13 | <0.0001 | −0.23 | 0.31 | 0.45 | 0.02 | 0.04 | 0.62 | −0.02 | 0.01 | <0.0001 |
Adjusted for speckle-tracking analyst, study site, image quality, and familial relatedness